B of A Securities Rates Alkermes (ALKS) sell, $38 Price Target

B of A Securities lowers its rating on Alkermes to sell with a $38 price target, a 27.49% downside from the current price.

By TradeTexts Research Desk · Published Jun 29, 2026, 9:01 AM EDT · Updated Jul 1, 2026, 9:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

B of A Securities rated Alkermes plc ($ALKS) "sell" with a $38 price target on June 29, 2026.

Since the rating, $ALKS is up 5.0% after 1 week, down 8.0% after 1 month and down 21.5% to date (from the $52.53 close on Jun 29, 2026).

ALKS Alkermes plc

$41.22 +45.86% year to date

Daily close · Oct 16, 2026

Key Points

B of A Securities downgraded Alkermes to a sell with a $38 price target on June 29, 2026.
B of A Securities's $38 price target implies 27.49% downside from Alkermes plc's ($ALKS) current $52.41 share price.
Alkermes, a healthcare firm, traded near $55.08 on Monday, with a market cap of $9.18 billion.
Insiders at Alkermes have sold shares recently, including EVP Craig Hopkinson on June 1, 2026.

Get $ALKS trade alerts by text

We text you when insiders, Congress or big funds trade $ALKS. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Alkermes plc alert may contain errors. Disclosures

B of A Securities has downgraded its rating on Alkermes plc (NasdaqGS: ALKS) to a sell, setting a new price target of $38. This change was made by analyst Jason Gerberry on June 29, 2026. Shares of Alkermes were trading around $55.08 on Monday.

Analyst rating track record

B of A Securities vs. the S&P 500

YTD return +4.74% hypothetical

All-time return +28.26% S&P 500 +23.59%

vs. S&P 500 +4.67% ahead of the index

Hypothetical returns from B of A Securities's disclosed trades, not real profit or advice. How we model this.

What Changed in B of A Securities' Alkermes Position

B of A Securities' analyst Jason Gerberry lowered the rating for Alkermes to a sell with a $38 target. This reflects a more cautious outlook on the company's future performance.

Other Institutional Activity in Alkermes

BlackRock, Inc. slightly increased its holdings in Alkermes by 41,998 shares, resulting in a total of 28,314,410 shares valued at around $1.00 billion. Vanguard Portfolio Management LLC opened a new position with 9,511,112 shares worth approximately $336.3 million. Meanwhile, Renaissance Technologies LLC reduced its stake by 507,600 shares, leaving it with 6,160,428 shares valued at $217.8 million.

Alkermes plc Stock Up 20.8%

On Monday, shares of Alkermes traded near $55.08. The company has a market capitalization of about $9.18 billion and a P/E ratio of 61.2. Its forward P/E stands at 35.39, and it has a beta of 0.334, indicating lower volatility compared to the market. The stock's 52-week range has been between $25.17 and $55.28, with a 50-day moving average of $39.51 and a 200-day moving average of $32.71. Alkermes maintains a current ratio of 2.27 and a quick ratio of 1.53.

12-month forecast

$ALKS price target

Alkermes plc daily closes and this analyst's $38 target. Not advice.

Recent Earnings

Alkermes reported revenues of approximately $1.56 billion, with a revenue growth rate of 28.2%. The company's net margin was 9.8%, and its return on equity stood at 9.4%. Alkermes is expected to release its next earnings report on July 28, 2026.

Insider Buying and Selling at Alkermes plc

Several insiders at Alkermes have been active recently. EVP Craig Hopkinson sold 9,000 shares on June 1, 2026, at an average price of $41.67 and bought 5,000 shares on the same day. Christopher Wright sold 2,000 shares on June 12, 2026, at $45.10. These transactions were part of planned sales.

Analysts Set New Price Targets

On June 29, 2026, B of A Securities downgraded Alkermes to a sell with a $38 price target. Other firms like Needham and TD Cowen maintained their buy ratings with targets of $61 and $50, respectively. Overall, the consensus recommendation remains a buy, with a mean target price of $48.13 based on 16 analyst opinions.

About Alkermes

Alkermes plc is a biopharmaceutical company headquartered in Dublin, Ireland. It focuses on developing and commercializing pharmaceutical products for unmet medical needs in areas such as opioid dependence, alcohol dependence, and schizophrenia. The company offers products like ARISTADA for schizophrenia and VIVITROL for alcohol dependence. Led by CEO Richard F. Pops, Alkermes employs around 2,050 people and collaborates with firms like Janssen Pharmaceutica.

Bottom Line

B of A Securities' downgrade of Alkermes to a sell reflects a shift in sentiment, with a new price target of $38. Investors should note that 13F filings are backward-looking and may not represent current positions. Alkermes' stock remains a focus due to its position in the healthcare sector and recent insider activity.